Letícia Cirelli Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Letícia Cirelli Ruiz has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina de Morais Oliveira-Scussel
Laboratory of Cell Interaction, Federal University of Triângulo Mineiro, Uberaba 38025-180, MG, Brazil
1 shared publication - Anielle Christine Almeida Silva
Federal University of Uberlândia
1 shared publication - Anna Victória Bernardes Borges
Department of Microbiology, Immunology and Parasitology, Federal University of Triângulo Mineiro, Uberaba 38025-180, MG, Brazil
1 shared publication - Carlo José Freire Oliveira
Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, Brazil
1 shared publication - Fernanda Bernadelli De Vito
Universidade Federal do Triângulo Mineiro
1 shared publication - Fernanda Rodrigues Helmo
Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba 38025-180, Minas Gerais, Brazil
1 shared publication
Latest Publications
- Open Access
- 29 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2642
Development of Ag-ZnO/AgO Nanocomposites Effectives for Leishmania braziliensis Treatment
Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. Leishmania braziliensis (L.b) is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for patients have significant toxicity, high dropout rates, high cost, and the emergence of resistant strains, which implies the need for studies to promote new and better treatments to combat the disease. Zinc oxide nanocrystals are microbicidal and immunomodulatory agents. Here, we develop new Ag-ZnO/xAgO nanocomposites (NCPs) with three different percentages of silver oxide (AgO) nanocrystals (x = 49%, 65%, and 68%) that could act as an option for tegumentary leishmaniasis treatment. Our findings showed that 65% and 68% of AgO inhibit the extra and intracellular replication of L.b. and present a high selectivity index. Ag-ZnO/65%AgO NCPs modulate activation, expression of surface receptors, and cytokine production by human peripheral blood mononuclear cells toward a proinflammatory phenotype. These results point to new Ag-ZnO/AgO nanocomposites as a promising option for L. braziliensis treatment.
- 29 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2642
Open AccessDevelopment of Ag-ZnO/AgO Nanocomposites Effectives for Leishmania braziliensis Treatment
Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. Leishmania braziliensis (L.b) is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for patients have significant toxicity, high dropout rates, high cost, and the emergence of resistant strains, which implies the need for studies to promote new and better treatments to combat the disease. Zinc oxide nanocrystals are microbicidal and immunomodulatory agents. Here, we develop new Ag-ZnO/xAgO nanocomposites (NCPs) with three different percentages of silver oxide (AgO) nanocrystals (x = 49%, 65%, and 68%) that could act as an option for tegumentary leishmaniasis treatment. Our findings showed that 65% and 68% of AgO inhibit the extra and intracellular replication of L.b. and present a high selectivity index. Ag-ZnO/65%AgO NCPs modulate activation, expression of surface receptors, and cytokine production by human peripheral blood mononuclear cells toward a proinflammatory phenotype. These results point to new Ag-ZnO/AgO nanocomposites as a promising option for L. braziliensis treatment.